PLEASANTON, Calif., Nov. 27, 2012 /PRNewswire/ -- TriReme Medical, Inc. and its affiliates (TriReme) announced today a new round of financing that brings a total of US$18 million into the group. The round is led by Luminor Capital of Singapore and includes major existing investors and new Asian investors. TriReme provides a range of innovative solutions for complex lesions and proceeds of the new round will go toward developing TriReme's pipeline of unique dilatation catheters and expanding its commercial infrastructure worldwide.
"We are thrilled to have this major support from Asia in our efforts to create a next generation of interventional devices, " stated Eitan Konstantino, Ph.D., President and CEO of TriReme Medical. "We share a vision of leaving no implant behind and will continue to focus on the large Asian markets in addition to the US."
"TriReme has demonstrated significant commercial and technical progress despite many challenges that the medical device community is facing," said Mr. Michael Kleine representing TriReme's board of directors. "Together with our new partners, we are looking forward to supporting the company in the commercialization of its breakthrough technologies."
In a related announcement, TriReme welcomes Mr. John Borrell as Vice President of Sales. Mr. Borrell is a seasoned sales executive with vast experience including senior management positions held at Covidien, CSI, and FoxHollow.
About TriReme Medical, Inc.
Based in Pleasanton, California and Singapore, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.